dm+d
Unassigned
New Medicines
Alzheimer's disease, mild-to-moderate
Information
New molecular entity
Cerecin
Cerecin
Development and Regulatory status
None
None
Phase III Clinical Trials
Category
Glucose stimulant
Alzheimer disease is the most common form of dementia, accounting for around 50% of cases, and is estimated to affect up to 500,000 people in the UK. Between 50% and 64% are estimated to have mild to moderately severe disease [2,3].
Alzheimer's disease, mild-to-moderate
Oral